TickerTalks
Browse all tickers →
TickerTalks›$ORKA
ORORKA

Oruka Therapeutics, Inc.

$ORKA·$5.0B·Biotechnology·Healthcare
$71.93-2.6%YTD+158.0%1Y+170.8%
Price updated 6h ago·X counts updated 5d ago
ORORKA
$ORKAOruka Therapeutics, Inc.
$71.93-2.63%82 posts1.1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $ORKA on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

82X posts · last 7 days
Sep 29Oct 11
Chatter Meter
1.1×
QuietNormal · 1×Loud

How loud $ORKA's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 79% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-08-17

Oruka Therapeutics chatter is bullish - Q2 update highlights include $1.1B in cash (fully funded through BLA filing), FDMC ~$7.7B at $100/share, orka-001 Phase 1 28-week data due late Q3 2026 (with 52-week data in December), and orka-001 Phase 2b fully enrolled early with 187 subjects. ORKA is grouped with REPL, IMNM, and PTGX as biotech names making new highs. One critic frames Fairmount as soaking capital across ORKA and SYRE.

Read what X is saying about $ORKA

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $ORKA — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-10-02

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Oruka is up 348% TTM on orka-001 for psoriasis — $1.1B cash runway through BLA and 28-week data due late Q3.

Oruka Therapeutics is a clinical-stage biotech developing orka-001 — a long-acting IL-23 inhibitor for plaque psoriasis designed to require infrequent dosing. The business is pre-revenue; the stock has gone up 4x in 12 months on the pipeline.

  • The business is pre-revenue: PS reads as zero, operating margin uninformative, PE -35x — standard biotech-clinical P&L where every number is R&D and the thesis is clinical cadence.
  • The cash position is specific: $1.1B in cash is fully funded through BLA filing — eliminating one of the biggest biotech risks (dilution before readouts); fully-diluted market cap ~$7.7B at $100/share equivalence.
  • The pipeline cadence is dated: orka-001 Phase 1 28-week data due late Q3 2026 (plus 52-week data in December) and the Phase 2b fully enrolled early with 187 subjects — concrete data triggers near-term.

Nov 11 Q3 earnings is the operational anchor; the 28-week and 52-week data readouts are the catalysts — clean durability data plus a solid Phase 2b readout extends the stock. Any safety signal or disappointment on dosing-interval economics and the stock gives back a chunk of the TTM gain.

Agrees with X sentimentThe thread has substantive drivers — $1.1B cash fully funded to BLA, ~$7.7B fully-diluted cap at $100 equivalence, orka-001 Phase 1 28-week due late Q3 2026, Phase 2b fully enrolled with 187 subjects, 52-week data in December — all specific pipeline milestones.

What to watch: Nov 11 Q3 earnings, the orka-001 Phase 1 28-week readout (late Q3), the 52-week data in December, and the Phase 2b top-line. A safety signal or dosing-interval disappointment is the hard invalidator.

On the calendar: 2026-11-11 — Q3 earnings

Read the AI verdict on $ORKA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing long-acting monoclonal antibodies (ORKA-001/002) for psoriasis and inflammatory diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ORKA.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $ORKA

Neutral — Clinical-stage biotech developing long-acting monoclonal antibodies (ORKA-001/002) for psoriasis and inflammatory diseases.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-34.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-27.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-2.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-26.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 10, 2026$-0.55$-0.51-7.3%
Q1 2026May 13, 2026$-0.48$-0.55+12.2%
Q4 2025Mar 12, 2026$-0.45$-0.61+26.2%
Q3 2025Nov 12, 2025$-0.55$-0.56+1.8%
Next earningsWed, Nov 11·consensus EPS $-0.60

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.58$-23.7M
Q4 FY25$0———$-0.54$-22.7M
Q3 FY25$0———$-0.69$-21.7M
Q2 FY25$0———$-0.58$-23.2M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$2.40-$2.63 – -$2.190
FY27$0$0 – $0-$2.83-$3.38 – -$2.160
FY28$0$0 – $0-$3.62-$6.08 – -$2.650
FY29$0$0 – $0-$4.05-$4.05 – -$4.050
FY30$155.9M$155.9M – $155.9M-$4.23-$4.23 – -$4.233

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.52%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-22.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+8.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 56.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-0.395-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellOct 15Joana GoncalvesChief Medical Officer7.0K sh$524KSellOct 12Arjun AgarwalPresident10.0K sh$806KSellOct 1Klein Lawrence OttoCEO25.0K sh$2.1MSellSep 21Arjun AgarwalPresident533 sh$51KSellSep 21Paul T QuinlanGeneral Counsel10.0K sh$936KSellSep 15Joana GoncalvesChief Medical Officer7.9K sh$734KSellSep 15Arjun AgarwalPresident560 sh$54KSellSep 15Klein Lawrence OttoCEO2.5K sh$235KSellSep 15Sandler Laura LeeCOO906 sh$87KSellSep 15Paul T QuinlanGeneral Counsel1.0K sh$99K
1–10 of 33
+ 22 other (20 exempts · 1 award · 1 conversion) in window

See when $ORKA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)Aug 28424B5
AI summary

Oruka Therapeutics (ORKA) filed a 424B5 prospectus supplement to offer and sell up to $500 million in common stock through an at-the-money (ATM) equity distribution program, with TD Cowen acting as sales agent under a Sales Agreement amended August 21, 2026. The ATM structure allows Oruka to sell shares incrementally into the market at prevailing prices, minimizing dilution impact compared to a traditional block offering. Proceeds are intended for general corporate purposes, which for a clinical-stage biotech typically means funding ongoing trials and operations. This is a capital runway extension tool rather than a discrete capital raise event.

3New insider — initial holdingsAug 253
AI summary

Oruka Therapeutics, Inc. (ORKA) filed a Form 3 initial beneficial ownership statement for Larry Todd Edwards, Chief Commercial Officer, as of August 24, 2026, at 855 Oak Grove Ave., Suite 100, Menlo Park, CA. The filing establishes Edwards's initial equity ownership baseline as a new Section 16 reporting officer. This is a routine administrative filing for a new executive officer at the dermatology-focused clinical-stage biotech.

8-KOfficer or director changeAug 248-K — Item 5.02: Officer or director change
AI summary

Oruka Therapeutics, Inc. (ORKA, Menlo Park CA), a clinical-stage biotech developing biologic treatments for chronic skin diseases, filed a current report on August 24, 2026 disclosing a change in executive officers or directors (Item 5.02) with exhibits. This is a companion to the concurrent Form 3 (Larry Edwards, CCO) filed on the same date, suggesting a new executive appointment. Leadership changes at clinical-stage biotechs are material for tracking management teams.

S-3Shelf registrationAug 21S-3
AI summary

Oruka Therapeutics, Inc. (ORKA, Menlo Park CA), a clinical-stage biotech developing biologics for chronic skin diseases, filed a shelf registration statement (Form S-3) on August 21, 2026, with General Counsel Paul Quinlan as contact and counsel Davis Polk & Wardwell LLP (Alan Denenberg, Elizabeth LeBow, Redwood City CA). The S-3 authorizes future securities offerings; specific scope is in the full document. This shelf filing accompanies the concurrent Form 3 (Larry Edwards, CCO) and 8-K (5.02 leadership change), suggesting active capital markets positioning for clinical development.

SC 13D/AActivist amendmentJul 1SC 13D/A
AI summary

Fairmount Funds Management LLC filed an amended Schedule 13D for ORKA (CUSIP 687604108), disclosing shared voting and dispositive power over 14,553,895 shares with zero sole power. Amendment to a previously disclosed 5%+ passive position.

8-KShareholder voteJun 48-K — Item 5.07: Shareholder vote
AI summary

Delaware 000-22873 36-3855489 disclosed voting results from its annual or special meeting. f Matters to a Vote of Security Holders. On June 2, 2026, Oruka Therapeutics, Inc. (the “ Company ”) held its Annual Meeting of Stockholders (the “ Annual Meeting ”). Set forth below is a brief description of each matter considered and voted upon at the Annual Meeting, together with the final tally of the number of votes cast for or against, as well as the number of abstentions and broker non-vote...

SC 13D/AActivist amendmentMay 4SC 13D/A
AI summary

Amendment No. 5 to Schedule 13D filed by Fairmount Funds Management LLC reporting beneficial ownership of ORUKA THERAPEUTICS, INC. representing a 9% stake (0 shares), with investment intent. This SC 13D/A filing dated 2026-05-04 updates the holder's position and disclosed intentions.

424B5Prospectus supplement (offering)Apr 29424B5
AI summary

ORKA filed a 424B5 prospectus supplement on 2026-04-29 of 9,660,000 Shares at $0.001 per share. This represents dilution happening now.

+ 14 other (5 13Gs · 2 10-Qs · 2 8-Ks · 2 424B5s) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Datazacks.com·23d agoOruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacybenzinga.com·24d agoOruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosingglobenewswire.com·24d agoOruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conferenceglobenewswire.com·37d agoORKA Stock Up More Than 60% in 3 Months: Here's What You Should Knowzacks.com·50d ago

In themes

Explore the broader themes this ticker is being talked about under.

Best Performers

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$IBRX$RXRX
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport